Patient preference-based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfactio

Phase 4

Recruiting

• Conditions: chronic kidney disease; end stage renal disease; 10029149

• Registration Number: NL-OMON55060
• Lead Sponsor: Amsterdam UMC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

• Age >= 18 years
• Haemodialysis patients (since at least 3 months)
• Necessity of phosphate binding therapy
• Written informed consent

Exclusion Criteria

• Intolerance of one of three types of phosphate binders
• Expected cessation of dialysis treatment within 6 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Patient satisfaction with phosphate treatment measured with the Treatment<br /><br>Satisfaction Questionnaire for Medication (TSQM, version II).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>At the end of the trial efficacy phase the following secondary endpoints will<br /><br>be determined:<br /><br>• Plasma phosphate (before the first hemodialysis session after the long<br /><br>interval).<br /><br>• Quality of life (SF-12 questionnaire)<br /><br>• Dialysis symptoms index (DSI)<br /><br>• Side effects phosphate binding therapy (questionnaire)<br /><br>• PTH and alkaline phosphatase levels<br /><br>• Adherence to the phosphate binders (questionnaire and pill count)</p><br>